製品番号: HY-B0101

フルコナゾール

(別名: Fluconazole; UK-49858)

21 Cited Publications

カスタマーレビュー

Based on 21 publication(s) in Google Scholar

Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against Candida albicans. Fluconazole inhibits C. albicans and Candida kefyr with IC₉₉s range from 0.20 μg/mL to 0.39 μg/mL.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.74%
CAS 番号: 86386-73-4
分子式: C₁₃H₁₂F₂N₆O
分子量:306.27

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fluconazole 構造式

CAS 番号: 86386-73-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (21)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Antibiotic アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	CC₅₀	>1000 μg/mL Compound: FLC	Cytotoxicity against human 16HBE by MTS assay Cytotoxicity against human 16HBE by MTS assay	[PMID: 34998904]
A549	EC₅₀	>62.5 μg/mL Compound: FLC	Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay	[PMID: 28395217]
A549	IC₅₀	>100 μg/mL Compound: FCZ	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 30318439]
A549	IC₅₀	>30 μM Compound: FLC	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
A549	IC₅₀	>50 μM Compound: 1; FLC, FCZ	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
A549	IC₅₀	>50 μM Compound: FLC	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
BEAS-2B	EC₅₀	>62.5 μg/mL Compound: FLC	Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay	[PMID: 28395217]
Caco-2	IC₅₀	>64 μg/mL Compound: FLC	Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 37975824]
H9c2	IC₅₀	>100 μg/mL Compound: FCZ	Cytotoxicity against rat H9c2 cells by MTT assay Cytotoxicity against rat H9c2 cells by MTT assay	[PMID: 30318439]
HEK293	IC₅₀	>250 μM Compound: Fluconazole	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 29626797]
HEK-293T	IC₅₀	>50 μM Compound: 1; FLC, FCZ	Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
HeLa	IC₅₀	>100 μg/mL Compound: Fluconazole	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 26848627]
HepG2	CC₅₀	>128 μg/L Compound: FLC	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay	[PMID: 33335669]
HepG2	IC₅₀	>100 μg/mL Compound: FCZ	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 30318439]
HepG2	IC₅₀	>250 μg/mL Compound: Fluconazole	Cytotoxicity against human HepG2 cells after 2 days by MTT assay Cytotoxicity against human HepG2 cells after 2 days by MTT assay	[PMID: 25740636]
HepG2	IC₅₀	>300 μM Compound: FLU	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 24953953]
HepG2	IC₅₀	>50 μM Compound: 1; FLC, FCZ	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
HepG2	IC₅₀	>50 μM Compound: FLC	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
HL-60	IC₅₀	11.6 μM Compound: Fluconazole	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
HT-29	IC₅₀	>100 μg/mL Compound: FCZ	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 30318439]
HUVEC	IC₅₀	>40 μM Compound: FLC	Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	[PMID: 32347094]
HUVEC	IC₅₀	>64 μg/mL Compound: FLC	Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 35922963]
HUVEC	IC₅₀	9.177 μg/mL Compound: FLC	Cytotoxicity against HUVEC cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Cytotoxicity against HUVEC cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 37975824]
K562	CC₅₀	385.2 μM Compound: 5	Cytotoxicity to reduce chronic myeloid leukemia K 562 cells Cytotoxicity to reduce chronic myeloid leukemia K 562 cells	[PMID: 15267229]
K562	CC₅₀	385.2 μM Compound: 5, fluconazole	Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay	[PMID: 18529046]
L6	IC₅₀	>294.1 μM Compound: fluconazole	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay	[PMID: 25580906]
L6	IC₅₀	9.967 μM Compound: fluconazole	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis	[PMID: 25580906]
LLC-PK1	IC₅₀	>10 μg/mL Compound: FLU	Cytotoxicity against LLC-PK1 cells by neutral red method Cytotoxicity against LLC-PK1 cells by neutral red method	[PMID: 17181171]
MCF7	IC₅₀	>30 μM Compound: FLC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
MCF7	IC₅₀	>50 μM Compound: 1; FLC, FCZ	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
MCF7	IC₅₀	>50 μM Compound: FLC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
MDA-MB-231	IC₅₀	19.21 μM Compound: Fluconazole	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
NIH3T3	IC₅₀	387 μg/mL Compound: fluconazole	Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT colorimetric assay	[PMID: 18032039]
PBMC	CC₅₀	676.43 μg/mL Compound: FLC	Cytotoxicity against PBMC (unknown origin) by MTT assay Cytotoxicity against PBMC (unknown origin) by MTT assay	[PMID: 34998904]
PBMC	IC₅₀	>16.32 μM Compound: Fluconazole	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 24485783]
PC-3	IC₅₀	16.49 μM Compound: Fluconazole	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
Peritoneal macrophage cell	IC₅₀	>100 μM Compound: Fluconazole	Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]
RAW264.7	IC₅₀	>50 μM Compound: FLC	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
THLE-2	IC₅₀	>30 μM Compound: FLC	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
THLE-2	IC₅₀	>50 μM Compound: FLC	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
U-937	CC₅₀	316 μM Compound: 5	Cytotoxicity to reduce human histolytic lymphoma U937 cells Cytotoxicity to reduce human histolytic lymphoma U937 cells	[PMID: 15267229]
U-937	CC₅₀	328 μM Compound: 5, fluconazole	Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay	[PMID: 18529046]
Vero	IC₅₀	>10 μg/mL Compound: FLU	Cytotoxicity against Vero cells by neutral red method Cytotoxicity against Vero cells by neutral red method	[PMID: 17181171]
Vero	IC₅₀	>100 μM Compound: Fluconazole	Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]

体外実験

Fluconazole inhibits 4 species ofAspergillus fumigatus with the IC₅₀s of 23.9-43.5 μg/mL. Fluconazole (0.20 μg/mL) inhibits significantly the mycelial-phase growth and germ tube elongation of C. albicans in a medium supplemented with serum^[1].
Fluconazole is a triazole antifungal agent that has been available for the treatment of infections due to Candida, Cryptococcus. The MIC₉₀ is highest for C. krusei (MIC ≥ 64 μg/mL) and C. glabrata (MIC, 32 μg/mL) and is ≤2 μg/mL for C. albicans (0.5 μg/mL), C. parapsilosis (2 μg/mL), C. tropicalis (2 μg/mL), C. lusitaniae (2 μg/mL), and C. kefyr (0.5 μg/mL)^[2].
Fluconazole (0.1-50.0 μg/mL) damages the fungal cells and reduces their viability^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

C.albicans yeast cells (strain ATCC 26310 and strain TW)
Concentration:

0.1, 0.5, 5.0, 50.0 μg/mL
Incubation Time:

24 hours
Result:

The MICs against both strains were 0.5 μg/mL.

体内実験

Fluconazole ( 0, 0.5, 1, 2.5, 5, 7.5, and 10 mg/kg; administered intraperitoneally (i.p.) as a single dose) results in a 50% reduction in fungal densities (ED50) of 4.87 mg/kg in a murine model of systemic candidiasis^[4]. Fluconazole exhibits terminal elimination half-life of 2.4 h) following i.p. administration.The terminal half-life does not change with the dose of fluconazole administered^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female NYLAR mice (weight, 18 to 20 g; infected intravenously with C. albicans blastoconidia)^[4]
Dosage:

5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis)
Administration:

Given i.p. as a single dose
Result:

T_1/2=2.4 h

化学情報

CAS 番号 86386-73-4
性状 Solid
分子量 306.27
分子式 C₁₃H₁₂F₂N₆O
Color White to off-white
SMILES

FC1=CC=C(C(O)(CN2C=NC=N2)CN3C=NC=N3)C(F)=C1
別名

Fluconazole; UK-49858
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (21)

All In Vivo Efficacy StudyMicrobiological AssayHistological Imaging/Staining

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Sci Adv

E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-κB activation. [Abstract]

2021 May 7;7(19):eabe5171. PMID: 33962939

Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]

Fungal burden of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.

Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]

Weight loss of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.

Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]

Colon length of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.

Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]

Histological analysis of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.
J Hazard Mater

Stereostructure-activity mechanism of cyproconazole by cytochrome P450 in rat liver microsomes: A combined experimental and computational study. [Abstract]

2021 Aug 15:416:125764. PMID: 33827004
Environ Int

A potential biomarker of isofenphos-methyl in humans: A chiral view. [Abstract]

2019 Jun:127:694-703. PMID: 30991225
Antioxidants (Basel)

Hyssopus cuspidatus Boriss Volatile Extract (SXC): A Dual-Action Antioxidant and Antifungal Agent Targeting Candida albicans Pathogenicity and Vulvovaginal Candidiasis via Host Oxidative Stress Modulation and Fungal Metabolic Reprogramming. [Abstract]

2025 Aug 25;14(9):1046. PMID: 41008953
Environ Pollut

Assessing environmental and human health risks: Insight from the enantioselective metabolism and degradation of fenpropidin. [Abstract]

2024 Aug 15:355:124214. PMID: 38801883
J Agric Food Chem

Enantioselective Metabolic Mechanism and Metabolism Pathway of Pydiflumetofen in Rat Liver Microsomes: In Vitro and In Silico Study. [Abstract]

2022 Mar 2;70(8):2520-2528. PMID: 35184556
Microb Biotechnol

Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species. [Abstract]

2022 Feb;15(2):482-498. PMID: 33955652

Fluconazole purchased from MedChemExpress. Usage Cited in: Microb Biotechnol. 2022 Feb;15(2):482-498. [Abstract]

Candida albicans (SC5314) was placed in YPD medium and serially diluted with fluconazole, panatinib, or both. OD600 values were measured every 15 minutes at 30°C, and FICI values were calculated according to the CLSI Broth Microdilution Reference Guide (M38-A)
Transl Res

A dual action small molecule enhances azoles and overcomes resistance through co-targeting Pdr5 and Vma1. [Abstract]

2022 Sep:247:39-57. PMID: 35452875
Front Microbiol

Ire1 inhibitors attenuate Candida albicans pathogenicity and demonstrate potential for application in antifungal therapy. [Abstract]

2025 Sep 3:16:1648467. PMID: 40969430
Probiotics Antimicrob Proteins

Screening the γ-core Motif Peptides of Ascomycetous Antifungal Proteins for Antifungal Activity and Potential Therapeutic Applicability. [Abstract]

2026 Jan 6. PMID: 41493708
Microchem J

2026 Mar 27.
Microbiol Spectr

Synergistic antifungal activity of minocycline as an effective augmenting agent of fluconazole against drug-resistant Candida tropicalis. [Abstract]

2025 May 6;13(5):e0318524. PMID: 40162832
Bioorg Med Chem

Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5. [Abstract]

2021 Aug 15:44:116293. PMID: 34243044
Drug Test Anal

High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]

2021 Feb;13(2):283-298. PMID: 32852861
J Mycol Med

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans. [Abstract]

2022 Mar;32(1):101227. PMID: 34800920
Open Life Sci

Effects of Ire1 gene on virulence and pathogenicity of Candida albicans. [Abstract]

2025 Apr 29;20(1):20221062. PMID: 40321158
Eur J Drug Metab Pharmacokinet

Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans. [Abstract]

2022 Sep;47(5):639-652. PMID: 35733077
University of Szeged

2026.
Orebro University

2024.
bioRxiv

2024 May 14.

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (326.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (6.53 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2651 mL

16.3255 mL

32.6509 mL

5 mM

0.6530 mL

3.2651 mL

6.5302 mL

10 mM

0.3265 mL

1.6325 mL

3.2651 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 2 mg/mL (6.53 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (283 KB)
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. H Yamaguchi, et al. [In vitro activity of fluconazole, a novel bistriazole antifungal agent]. Jpn J Antibiot. 1989 Jan;42(1):1-16. [Content Brief]

[2]. M A Pfaller, et al. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006 Apr;19(2):435-47. [Content Brief]

[3]. P G Sohnle, et al. Effect of fluconazole on viability of Candida albicans over extended periods of time. Antimicrob Agents Chemother. 1996 Nov;40(11):2622-5. [Content Brief]

[4]. A Louie, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 1998 May;42(5):1105-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.2651 mL	16.3255 mL	32.6509 mL	81.6273 mL
H₂O / DMSO	5 mM	0.6530 mL	3.2651 mL	6.5302 mL	16.3255 mL
DMSO	10 mM	0.3265 mL	1.6325 mL	3.2651 mL	8.1627 mL
	15 mM	0.2177 mL	1.0884 mL	2.1767 mL	5.4418 mL
	20 mM	0.1633 mL	0.8163 mL	1.6325 mL	4.0814 mL
	25 mM	0.1306 mL	0.6530 mL	1.3060 mL	3.2651 mL
	30 mM	0.1088 mL	0.5442 mL	1.0884 mL	2.7209 mL
	40 mM	0.0816 mL	0.4081 mL	0.8163 mL	2.0407 mL
	50 mM	0.0653 mL	0.3265 mL	0.6530 mL	1.6325 mL
	60 mM	0.0544 mL	0.2721 mL	0.5442 mL	1.3605 mL
	80 mM	0.0408 mL	0.2041 mL	0.4081 mL	1.0203 mL
	100 mM	0.0327 mL	0.1633 mL	0.3265 mL	0.8163 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Fluconazole

21 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

フルコナゾール

Antifungal Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Nephrotoxicity Compound Library

MCE Kinase Hinge Binder Fragment Library

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

MedChemExpress（MCE）の使用を引用している文献 Fluconazole

Antibiotic アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (21)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Fluconazole 関連分類

HY-B0101 関連分類